a busy week !3 Mar 2020 07:13
Scancell Holdings plc (“Scancell” or the “Company”)
Scancell to present at three research conferences, illustrating some of the recent progress on its platform technologies
Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that its Chief Scientific Officer and Professor of Cancer Immunotherapy at the University of Nottingham, Professor Lindy Durrant, Ph.D., will be presenting at the following three conferences in March 2020:
The Cambridge Healthcare Institute’s (CHI) Immuno-Oncology Summit Europe 2020 in London (9th – 12th March 2020)
The 4th Annual MarketsandMarkets Next Gen Immuno-Oncology Congress in London (12th – 13th March 2020)
The 5th Skin Vaccination Summit 2020 in Edinburgh (17th March 2020 – 19th March 2020)
The presentations by Professor Durrant will highlight the recent progress made across the Company’s technology platforms including Moditope® and AvidiMab™.
At the CHI Summit, Professor Durrant will give a featured presentation on Tuesday 10th March entitled ‘Stress induced post-translational modifications (siPTMs) as targets for cancer vaccines’ focusing on citrullination as a widely expressed, novel, stress induced post-translational modification that is a potent target for cancer vaccines such as those based on Scancell’s Moditope® platform.
The focus of the MarketsandMarkets Next Gen Immunology Congress is on developments in the field of monoclonal antibodies including antibody drug conjugates, bispecific antibodies, biomarkers, T cell receptor (TCR) approaches and CART-T cell therapies. Professor Durrant will give a presentation on Thursday 12th March entitled ‘AvidMabs, Fc engineering to enhance the avidity of monoclonal antibodies’ focusing on Scancell’s new antibody engineering technology, AvidiMab™, and the identification of a panel of antibodies that recognise tumour-assoicated glycans.
The Skin Vaccination Summit will concentrate on the skin as an ideal target to induce potent immune responses and more efficacious vaccines. On Wednesday 18th March Professor Durrant will present ‘Targeting citrullinated vimentin and enolase with cytotoxic CD4 T cells relies upon MHC-II expression by tumors, reduces myeloid suppressor cells and directly kills tumor cells’ describing the translation of its lead Moditope® vaccine, Modi-1, into a intradermal immunotherapy with clinical utility for patients with solid tumours.
The company has also previously presented data at the British Society for Immunology Congress held in Liverpool in December 2019. Members of Professor Durrant’s research team presented two posters, including one on the further scientific understanding of the Moditope® platform and one on FG2811, its ultra-specific antibody with the ability to induce human stem memory T cell proliferation and differentiation, and the potential to be utilised in vivo for cancer immunotherapy or to provide cells for CAR-T or T
Sign In
Follow the stocks
